Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vimta LabsBOM:524394 +3.58%84 Market Cap is ₹28,653 Mil as of Aug. 05, 2026. GuruFocus rates BOM:524394 with a GF Score™ of 84/100 and a GF Value™ of ₹495.16 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 217 Medical Diagnostics & Research companies, Vimta Labs ranks better than 64.52% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Vimta Labs's share price for the quarter that ended in Jun. 2026 was ₹587.6. Vimta Labs's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 45 Mil. Therefore, Vimta Labs's market cap for the quarter that ended in Jun. 2026 was ₹26,258 Mil.
Vimta Labs's quarterly market cap
declined
from Dec. 2025 (₹27,058 Mil) to Mar. 2026 (₹17,010 Mil) but then
increased
from Mar. 2026 (₹17,010 Mil) to Jun. 2026 (₹26,258 Mil).
Vimta Labs's annual market cap
increased
from Mar. 2024 (₹9,857 Mil) to Mar. 2025 (₹22,237 Mil) but then
declined
from Mar. 2025 (₹22,237 Mil) to Mar. 2026 (₹17,010 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Vimta Labs's Enterprise Value for Today is ₹28,018 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Vimta Labs Market Cap Related Terms
Vimta Labs Market Cap Historical Data
* Premium members only.
The historical data trend for Vimta Labs's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524394 vs TMO, DHR, IDXX: Market Cap Comparison
For the Diagnostics & Research subindustry, Vimta Labs's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vimta Labs Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vimta Labs's Market Cap distribution charts can be found below:
* The bar in red indicates where Vimta Labs's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Vimta Labs's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vimta Labs (BOM:524394) has a Market Cap of ₹28,653 Mil as of Aug. 05, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Vimta Labs and its competitors. According to the industry distribution chart, Vimta Labs ranks #77 out of 217 companies in the Medical Diagnostics & Research industry, placing it in the top 35.5%.
Is Vimta Labs' Market Cap too high?
Vimta Labs' current Market Cap is ₹28,653 Mil. Based on the distribution chart, Vimta Labs ranks #77 out of 217 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Vimta Labs has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vimta Labs' Market Cap compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimta Labs ranks #77 out of 217 companies for Market Cap. This puts Vimta Labs in the upper half of its industry. The industry median Market Cap is 59.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 59.04, based on 217 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Vimta Labs and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 59.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vimta Labs's current Market Cap is ₹28,653 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimta Labs stock overvalued right now?
Based on GuruFocus' analysis, Vimta Labs (BOM:524394) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹495.16, compared to a current price of ₹641.20 — trading 29.5% above its estimated fair value. The current Market Cap is ₹28,653 Mil. Vimta Labs' overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Vimta Labs (BOM:524394), the current Market Cap is ₹28,653 Mil as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimta Labs (BOM:524394) Overvalued in 2026?
Based on GuruFocus' analysis, Vimta Labs stock appears to be overvalued.
The current stock price of ₹641.20 is trading 29.5% above its estimated GF Value™ of ₹495.16.
GuruFocus considers Vimta Labs to be Modestly Overvalued.
Key valuation signals for BOM:524394:
Market Cap: ₹28,653 Mil
GF Value™: ₹495.16 vs. price of ₹641.20 (29.5% above fair value)
No single metric tells the full story. See the BOM:524394 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimta Labs Ltd is a comprehensive contract research and testing organization, providing a wide range of services to pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, and many other industries. Its services portfolio includes testing and contract research services in the fields of clinical research, pre-clinical research, clinical diagnostics, biopharma services, analytical testing, research and environmental studies, and Others. It has only one reportable segment namely Contract Research and Testing Services which generates the revenue.
84GF Score
Get the complete analysis for BOM:524394
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524394 has been successfully added to your 
